<div id="readability-page-1"><div id="parent_top_div"><p>Sun Pharmaceutical has announced that its subsidiary, Taro Pharmaceuticals, has entered into an agreement to acquire a 100 per cent stake in Antibe Therapeutics, a clinical-stage biotechnology company based in Ontario, Canada.</p> <p>  The acquisition is expected to be completed before March 7, 2025, subject to approval from the Ontario Superior Court of Justice.</p> <p>  The transaction is part of Sun Pharma’s strategy to expand its pharmaceutical and healthcare portfolio, particularly in the area of pain and inflammation management. Antibe Therapeutics specialises in developing novel drugs focused on reducing pain and inflammation.</p> <p>  Founded in 2009, the company is currently under court-appointed receivership and has reported no revenue for the past three years.</p> <p>  Sun Pharma has stated that the acquisition consideration will be in cash, but the amount will not be disclosed until the transaction closes, due to court oversight of the divestiture of Antibe.</p> <p>  “Sun Pharma shall update the consideration to stock exchanges once the transaction is completed,” the company stated in an exchange filing.</p> <p>On the same day, Sun Pharma’s stock rose 0.38 per cent to Rs 1,763.50 apiece on Thursday.</p></div></div>

Taro药业

<p>Sun Pharmaceutical 的子公司 Taro Pharmaceuticals 将收购位于加拿大安大略省的临床阶段生物技术公司 Antibe Therapeutics 的 100% 股份。此交易旨在增强 Sun Pharma 在疼痛和炎症管理领域的产品组合，预计将在 2025 年 3 月 7 日之前完成，待法院批准。Antibe 成立于 2009 年，已处于接管状态，并且在过去三年内没有产生收入。此次收购将以现金方式进行，具体细节将在交易后披露。公告发布后，Sun Pharma 的股价上涨了 0.38%，达到了 1,763.50 印度卢比</p>

太阳制药的子公司 Taro 将收购 Antibe Therapeutics 的全部股权